ClinicalTrials.gg
Not yet recruitingNCT07943325DELAYUpdated Nov 17, 2026

Delayed Application of Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer

A Phase 3 interventional study of Cisplatin and Carboplatin in Advanced NSCLC and Metastatic NSCLC - Non-Small Cell Lung Cancer, sponsored by Goethe University. Not yet recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Goethe University · Phase 3, Interventional, and Treatment

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
198
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 617 studies in Carcinoma, Non-Small-Cell Lung with a site in Germany — 102 open to participants now, 212 under way, 101 of them phase 3. Carcinoma, Non-Small-Cell Lung · Germany.

Planned enrollment
312th of 563
198 · median 245
Started
2027
the only one that year
Phase 3
225 of 617
38 open now
Primary completion
2032-02
later than 201 of 211 live
Registered
617th of 617
by date

Among the 617 studies in Carcinoma, Non-Small-Cell Lung with a site in Germany, this one is the 312th largest by planned enrollment of the 563 interventional ones that give a count, is the only one that started in 2027, is one of 225 in phase 3, reaches primary completion later than 201 of the 211 other live ones, and was the 617th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

102 of the 617 studies in Carcinoma, Non-Small-Cell Lung with a site in Germany are open now. Recruiting first, the newest first:

97 more — sign in →

All 102 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 617 studies in Carcinoma, Non-Small-Cell Lung with a site in Germany, or all of them as a file.
02

Study summary

This study is a multicenter, randomized, open-label phase 3 trial of delayed administration of immunotherapy in patients who are planned to receive chemoimmunotherapy for newly diagnosed, advanced or metastatic, PD-L1 positive NSCLC without sensitizing alterations in EGFR, ALK, or ROS1.

Read the detailed description

This study enrolls patients with newly diagnosed, PD-L1 positive (PD-L1 TPS ≥ 1%), EGFR/ALK/ROS1-wildtype/-negative, advanced or metastatic non-small cell lung cancer who have not yet received systemic treatment.

Patients are randomized into two treatment arms. In both arms, patients receive standard treatment with histology-guided chemotherapy in combination with the PD-1 inhibitor cemiplimab. Patients in the experimental arm receive chemotherapy on Day 1 and cemiplimab on Day 4 of each cycle. Patients in the control arm receive both therapies on Day 1 of each cycle. After 4 cycles, patients continue with cemiplimab either with or without pemetrexed as per standard of care.

The time interval between chemotherapy and immunotherapy is intended to minimize antagonistic effects of chemotherapy on immunotherapy while simultaneously enhancing potential synergistic effects between the two treatment modalities.

03

Conditions studied

  • Advanced NSCLC
  • Metastatic NSCLC - Non-Small Cell Lung Cancer

Keywords

  • DELAY
  • NSCLC
  • advanced non-small cell lung cancer
  • metastatic non-small cell lung cancer
  • Immune Checkpoint Inhibitors
  • Delayed Application
  • Chemoimmunotherapy
  • Treatment optimization
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provided written
  2. Patients must be at least 18 years old
  3. Patients with or cytologically confirmed locally advanced (stage IIIB-C per UICC 9th edition) or (stage IV) non-small cell lung cancer (NSCLC) who are not candidates for treatment in curative intent including resection and/or definitive chemoradiotherapy, and who have received no prior systemic treatment for recurrent or metastatic NSCLC Note: Patients who received systemic therapies as part of a surgical and/or radiotherapeutic treatment with curative intent (including concomitant, , adjuvant and/or maintenance therapies) and developed recurrent or metastatic disease more than 12 months after completing therapy are eligible
  4. Positive tumor status defined as PD-L1 tumor proportion score ≥1% (local testing)
  5. No sensitizing alterations in EGFR, ALK or ROS1 (local testing)
  6. At least one (measurable) target lesion according to version 1.1. Target lesions may be located in a previously irradiated field if there is documented (radiographic) disease progression in that site.
  7. Planned treatment with an anti-PD-(L)1 inhibitor plus platinum-based chemotherapy
  8. Adequate organ function

    1. ≥ 9g/dl, ≥ 1500/mm³, ≥ 100.000/µL
    2. Estimated (GFR) ≥30ml/min/1.73m²
    3. ≤1.5 x , and ALT ≤ 3 x ULN Note: in the case of hepatic involvement, the following criteria apply: Bilirubin ≤3 x ULN, AST and ALT ≤ 5 x ULN
  9. The patient is willing and able to comply with the protocol for the duration of the study, including visits for treatment and scheduled follow-up visits and examinations

Exclusion criteria

Exclusion Criteria:

  1. Symptomatic, neurologically unstable or requiring increasing doses of to manage CNS symptoms within 2 weeks prior to study entry (maximal acceptable dose must be ≤10 mg of prednisolone or equivalent).

    Note: Patients with asymptomatic, incidentally detected CNS metastases may be enrolled. Palliative radiotherapy for asymptomatic brain metastases (and any other, non-brain metastases, e.g. bone ) may be conducted after study entry.

  2. Patients with or spinal cord compression
  3. Concurrent enrollment in another interventional trial. Participation in observational studies is acceptable
  4. Presence of cardiovascular disease, as defined by:

    1. (NYHA) heart failure classifications of class III, or IV; or myocardial infarction, or acute coronary syndrome within 12 months of first dose of study medication; or
    2. or stroke within 1 year
  5. Patients with a history of another that is either untreated or was treated within the past 3 years, with the exception of malignancies with a low risk of recurrence, such as adequately treated non-melanoma skin cancer, cervical carcinoma in situ, localized prostate cancer or ductal carcinoma in situ. Other similar cases can be considered after discussion with the coordinating investigator
  6. Patients who are unable to consent because they do not understand the nature, significance and implications of the clinical trial and therefore cannot form a rational intention in the light of the facts
  7. Patient who has been incarcerated or involuntarily institutionalized by court order or by the authorities Exclusion criteria related to autoimmunity, autoinflammation and immunodeficiency
  8. Any condition that requires ongoing/continuous corticosteroid therapy (>10 mg prednisone/day or anti-inflammatory equivalent) within 1 week prior to the first dose of study medication. Participants who require a brief course of steroids (up to 2 days in the week before enrollment) or physiologic replacement are not excluded.
  9. Ongoing or recent evidence of significant or inflammatory disease that required treatment with systemic treatments within the last 2 years.

    Note: The following are not exclusionary: non-bullous skin conditions (e.g., vitiligo), endocrinopathies (such as hypothyroidism or type 1 diabetes) that require only hormone replacement. Other similar cases may be eligible upon consultation with the coordinating investigator.

  10. History of interstitial lung disease (e.g., idiopathic pulmonary fibrosis or organizing pneumonia), of active, non-infectious pneumonitis that required immunosuppressive doses of glucocorticoids to assist with management, or of pneumonitis within the last 5 years. A history of radiation pneumonitis in the radiation field is not exclusionary
  11. History of solid organ or hematopoietic stem cell transplantation. Corneal transplantation is not exclusionary Exclusion criteria relating to infections
  12. Uncontrolled infection with , or infection, diagnosis of immunodeficiency, and/or tuberculosis (active or latent)

    a) Participants with known controlled HIV infection (undetectable viral load on HIV RNA PCR) and above 350/µl either spontaneously or on a stable antiviral regimen are eligible. For these participants monitoring will be performed per local standards.

    b) Participants with HBsAg positive who have controlled infection (serum HBV DNA PCR that is below the limit of detection and receiving anti-viral therapy for hepatitis B) are eligible. Participants with controlled infections must undergo periodic monitoring of HBV DNA. Participants must remain on anti-viral therapy for at least 6 months beyond the last dose of study medication.

    c) Participants with HBsAg negative but total HBcAb positive are permitted with the following requirements: If serum HBV DNA PCR is above the limit of detection at screening, initiate HBV antiviral therapy before study entry. If serum HBV DNA PCR is below the limit of detection, periodic monitoring of HBsAg must be performed.

    d) Participants who are HCV Ab+ who have controlled infection (undetectable HCV RNA by PCR either spontaneously or in response to a successful prior course of anti-HCV therapy) are eligible Exclusion criteria relating to vaccines

  13. Receipt of a within 4 weeks of start of study medication
  14. Receipt of COVID-19 vaccination within 1 week of planned start of study medication or for which the planned COVID-19 vaccinations would not be completed 1 week prior to start of study medication.

    Exclusion criteria relating to pregnancy and

  15. Women who are pregnant or breast-feeding
  16. * and men** who are unwilling to practice highly effective contraception prior to the initial dose/start of the first treatment, during the study, and for at least 4 months after the last dose. Highly effective contraceptive measures include:

    1. Stable use of combined (estrogen and progestogen containing) hormonal contraception (oral, intravaginal, transdermal) or progestogen-only hormonal contraception (oral, injectable, implantable) associated with inhibition of ovulation initiated 2 or more menstrual cycles prior to screening;
    2. Intrauterine device; intrauterine hormone-releasing system;
    3. Bilateral tubal occlusion/ligation;
    4. Vasectomized partner (provided that the male vasectomized partner is the sole sexual partner of the WOCBP study participant and that the vasectomized partner has obtained medical assessment of surgical success for the procedure); and/or
    5. Sexual abstinence†,‡. Pregnancy testing and contraception are required for WOCBP. Pregnancy testing and contraception are not required for women who are or permanently sterile.

      • WOCBP are defined as women who are fertile following menarche until becoming postmenopausal, unless permanently sterile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy, and bilateral oophorectomy.

      A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A high FSH level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy. However, in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient to determine the occurrence of a postmenopausal state. The above definitions are according to the CTFG guidance. Pregnancy testing and contraception are not required for women with documents hysterectomy or tubal ligation.

      **Male participants: A male participant will be excluded from the study if that participant does not agree to use condoms or practice sexual abstinence†‡, unless vasectomized, prior to the initial dose/start of study medication, during the study, and for at least 4 months after the last dose. Sperm donation is also prohibited during the same period. Vasectomy success must be confirmed by semen analysis.

      †Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study drugs. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the participant.

      ‡Periodic abstinence (calendar, symptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides only, and lactational amenorrhea method are not acceptable methods of contraception. Female condom and male condom should not be used together.

Terms in these criteria, in plain language(30)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
198 participants (estimated)

Study arms

  • Experimental
    Delayed Chemoimmunotherapy

    4 courses of cisplatin/carboplatin D1 + pemetrexed/paclitaxel D1 + cemiplimab D4 every 3 weeks, followed by maintenance cemiplimab ± pemetrexed

    Drug: Cisplatin · Drug: Carboplatin · Drug: Pemetrexed · Drug: Paclitaxel · Drug: Cemiplimab

  • Active comparator
    Concurrent Chemoimmunotherapy

    4 courses of cisplatin/carboplatin D1 + pemetrexed/paclitaxel D1 + cemiplimab D1 every 3 weeks, followed by maintenance cemiplimab ± pemetrexed

    Drug: Cisplatin · Drug: Carboplatin · Drug: Pemetrexed · Drug: Paclitaxel · Drug: Cemiplimab

Interventions

  • DrugCisplatin

    Dose per standard-of-care

  • DrugCarboplatin

    Dose per standard-of-care

  • DrugPemetrexed

    Dose per standard-of-care

  • DrugPaclitaxel

    Dose per standard-of-care

  • DrugCemiplimab

    Dose per standard-of-care

06

What researchers measure

Primary outcomes

  1. PFS

    Progression-free survival (PFS), defined as time from randomization until the first documented progression per investigator-assessed RECIST 1.1 criteria or death due to any cause, whichever occurs first

    Time frame: max. 60 months

Secondary outcomes

  1. ORR

    Objective response rate (ORR) is defined as the number of patients achieving a complete or partial response per investigator-assessed RECIST 1.1 criteria as best overall response divided by the number of patients

    Time frame: max. 60 months

  2. OS

    Overall survival (OS) is defined as the time from randomization to the date of death due to any cause

    Time frame: max. 60 months

  3. DOR

    Duration of response per investigator-assessed RECIST 1.1 is defined as the time between the first detection of complete or partial response, whichever occurs earlier, and disease progression or death. DOR will be calculated in patients who achieve a complete or partial response.

    Time frame: max. 60 months

  4. DCR

    Disease control rate (DCR) is defined as the number of patients achieving a complete or partial response or stable disease per investigator-assessed RECIST 1.1 criteria divided by the number of patients

    Time frame: max. 60 months

  5. Frequency and severity of immune-related adverse events (irAEs)

    Time frame: max. 60 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2027; primary completion for Feb 2032, 60 months later.

Of 109 non-industry phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 49 and three quarters within 129. This study's planned 60 months is below that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2026
First posted
Nov 17, 2026
StartEst.
Feb 2027
Primary completionEst.
Feb 2032
CompletionEst.
Feb 2032
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07943325
Lead sponsor
Goethe University
Collaborators
Regeneron Pharmaceuticals, Medical Oncology Working Group in the German Cancer Society (AIO)
Responsible party
Fabian Acker (Principal Investigator, Goethe University) — Principal investigator
First posted
Nov 17, 2026
Start date
Feb 2027 (estimated)
Primary completion
Feb 2032 (estimated)
Completion
Feb 2032 (estimated)
Last update
Nov 17, 2026

Study contacts

Fabian Acker, Dr.
principal investigator · Goethe University Frankfurt, University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion